• OFID 2018:5 (Suppl 1) • Poster Abstracts stays, and increased healthcare costs. This study aims to evaluate current practices of candidemia management and review associated clinical outcomes to identify potential targets for antifungal stewardship.
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1 Pharmacy, Dong-A University Hospital, Busan, Korea, Republic of (South) and 2 Infectious Diseases, Dong-A University Hospital, Busan, Korea, Republic of (South) Session: 56. Fungal Disease: Management and Outcomes Thursday, October 4, 2018: 12:30 PM Background. Anidulafungin has been prescribed in patients with candidemia, especially hepatic or renal dysfunction because of not undergoing metabolism in the liver and kidney. The purpose of this study was to evaluate the safety of anidulafungin in these patient populations.
Methods. We retrospectively reviewed the electronic medical records of candidemia in 146 patients who were treated with anidulafungin for more than 7 days at Dong-A University Hospital from January 2012 to December 2017. We evaluated changes in AST, ALT, and total bilirubin (TB) between the start and end of anidulafungin therapy, and change in estimated GFR (eGFR), calculated by the Modification of Diet in Renal Disease (MDRD) study equations.
Results. There were 101 patients with impaired liver function at the start of anidulafungin therapy (group A) and 57 with renal insufficiency (group B). In group A, 61 (60%) were male and the median age was 69 (20-88) years. The patients had solid tumor (51, 50%) and 26 (26%) were with liver disease. According to the Child-Pugh score, 54 (53%) patients were class B and five (5%) were class C. The median changes in AST, ALT, and TB during anidulafungin therapy were −10 U/L, −8 U/L, −0.3 mg/dL (P = 0.023, P = 0.008, P = 0.013), respectively ( Figure 1A) . In group B, 35 (61%) were male and the median age was 71 (20-88) years. There were 21 (37%) patients with solid tumor and 30 (53%) had kidney disease. The median change of eGFR was +6.6 mL/minute/1.73 m 2 (P < 0.001) ( Figure 1B ). Over 75% (ALT, AST, eGFR) and nearly 60% (TB) of patients had favorable changes (values were stable or improved) in hepatic or renal function during the anidulafungin therapy ( Figure 2 ).
Conclusion. Anidulafungin was tolerable for the treatment of candidemia in patients with hepatic or renal damage. Methods. We performed a retrospective analysis of hospitalized patients with CBSI at a large tertiary referral hospital between January 2007 and January 2015. Data were collected on demographics, comorbidities, medications, procedures, central lines, vital signs, and laboratory values. Univariate and multivariable logistic regression analyses were used to build the predictive model. Variables with P < 0.25 were considered for the multivariable analysis, and only those that remain significant (P < 0.05) were retained in the final model.
Predictive Model for Fluconazole Resistance in Patient With
Results. We identified 1,083 patients with CBSI, of whom 684 patients had azole susceptibility data available. Among cases with available resistance data, C. glabrata was the most common species isolated, occurring in 240 cases (38%), followed by C. parapsilosis, 176 cases (25.7%), and C. albicans, 121 cases (17.6%). One hundred thirynine isolates were found to have fluconazole resistance (C. glabrata 55, C. krusei 36). Eighty-three variables were considered in the multivariable analysis; nine remained significant and were included in our final model. Conclusion. We identified nine risk factors that were significantly associated with fluconazole resistance. By creating a predictive model, patients at higher or lower risk for resistance may be identified earlier which may assist in the choice of initial antifungal treatment.
Disclosures. All authors: No reported disclosures. Background. VADs are increasingly utilized in the management of end-stage heart disease. Infections are frequently encountered in VAD patients, are difficult to manage, and delay heart transplant. Prior studies have illustrated that fungal infections are rarer than bacterial infections but carry a higher mortality rate. Published data regarding the treatment and outcomes of fungal infections in VAD patients are scarceThe objective of this study was to describetreatment patterns, clinical outcomes and antifungal resistance rates in this unique patient population.
High Resistance and Mortality Rates in Patients With
Methods. This was a retrospective cohort study that included VAD patients 18 years and older admitted to Baylor St. 
